Bimatoprost

Bimatoprost
Clinical data
Trade namesLumigan, others
AHFS/Drugs.comMonograph
MedlinePlusa602030
License data
Pregnancy
category
Routes of
administration		eye drops
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityLow
Protein binding88%
Onset of action4 hrs
Elimination half-life45 min after intravenous application
Duration of action≥ 24 hrs
Excretion67% Kidney, 25% fecal
Identifiers
  • 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.170.712 Edit this at Wikidata
Chemical and physical data
FormulaC25H37NO4
Molar mass415.574 g·mol−1
3D model (JSmol)
  • CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1
  • InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1 checkY
  • Key:AQOKCDNYWBIDND-FTOWTWDKSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma.[5] Specifically it is used for open angle glaucoma when other agents are not sufficient.[5][6] It may also be used to increase the size of the eyelashes.[3][4] It is used as an eye drop and effects generally occur within four hours.[5][4]

Common side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts.[5][6][4] Use during pregnancy or breastfeeding is generally not recommended.[1][6][4] It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.[5]

Bimatoprost was approved for medical use in the United States in 2001.[5] It is available as a generic medication.[6][3][7] In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[8][9]

  1. ^ a b "Bimatoprost ophthalmic (Lumigan) Use During Pregnancy". Drugs.com. 14 October 2019. Retrieved 4 January 2020.
  2. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  3. ^ a b c "Bimatoprost solution/ drops". DailyMed. 18 September 2019. Retrieved 4 January 2020.
  4. ^ a b c d e "Lumigan- bimatoprost solution/ drops". DailyMed. 31 July 2017. Retrieved 4 January 2020.
  5. ^ a b c d e f "Bimatoprost Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.
  6. ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1149. ISBN 9780857113382.
  7. ^ "Bimatoprost". Drugs.com. 2 December 2019. Retrieved 4 January 2020.
  8. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  9. ^ "Bimatoprost Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.